Bristol-Myers Squibb stock hits 52-week low at 43.89 USD

Published 31/07/2025, 14:32
© Reuters.

Bristol-Myers Squibb (NYSE:BMY) stock reached a 52-week low, touching 43.89 USD, amid a year marked by volatility and challenges in the pharmaceutical sector. The company, which offers a substantial 5.39% dividend yield and has maintained dividend payments for 55 consecutive years, appears undervalued according to InvestingPro analysis. Over the past year, the stock has experienced a decline of 4.55%, reflecting broader market trends and specific company developments. This 52-week low highlights the pressures faced by the company, as it navigates a competitive landscape and seeks to maintain its position in the industry. Investors are closely monitoring the stock’s performance, looking for signs of recovery or further declines in the coming months. InvestingPro subscribers have access to 11 additional exclusive tips and a comprehensive Pro Research Report for deeper analysis of BMY’s potential.

In other recent news, Bristol Myers Squibb has announced several key developments. The company, in collaboration with Bain Capital, has formed a new independent biopharmaceutical entity focused on autoimmune therapies, supported by a $300 million financing commitment. This new venture will develop five immunology assets, including afimetoran, which is currently in Phase 2 trials for systemic lupus erythematosus. Additionally, the U.S. Food and Drug Administration has accepted Bristol Myers Squibb’s supplemental New Drug Application for Sotyktu, aimed at treating psoriatic arthritis, with a target action date set for March 2026.

In another update, Bristol Myers Squibb reported that its Phase 3 INDEPENDENCE study of Reblozyl for myelofibrosis-associated anemia did not meet its primary endpoint. The study narrowly missed statistical significance, although some patients showed a clinically meaningful improvement. Meanwhile, Cantor Fitzgerald has maintained its Neutral rating on Bristol Myers Squibb, following the announcement of the new immunology-focused entity. These developments highlight the company’s ongoing efforts in drug development and strategic partnerships.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.